LEADER 03360nam 2200625Ia 450 001 9910778373703321 005 20230721031813.0 010 $a0-309-17951-3 010 $a1-281-09356-4 010 $a9786611093563 010 $a0-309-11159-5 035 $a(CKB)1000000000479985 035 $a(EBL)3378302 035 $a(SSID)ssj0000111986 035 $a(PQKBManifestationID)11819475 035 $a(PQKBTitleCode)TC0000111986 035 $a(PQKBWorkID)10086242 035 $a(PQKB)10701129 035 $a(MiAaPQ)EBC3378302 035 $a(Au-PeEL)EBL3378302 035 $a(CaPaEBR)ebr10197086 035 $a(CaONFJC)MIL109356 035 $a(OCoLC)923277702 035 $a(EXLCZ)991000000000479985 100 $a20071113d2007 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 04$aThe Biological Threat Reduction Program of the Department of Defense$b[electronic resource] $efrom foreign assistance to sustainable partnerships /$fCommittee on Prevention of Proliferation of Biological Weapons, Office for Central Europe and Eurasia, Development, Security and Cooperation, Policy and Global Affairs, National Research Council of the National Academies 210 $aWashington, D.C. $cNational Academies Press$d2007 215 $a1 online resource (121 p.) 300 $aDescription based upon print version of record. 311 $a0-309-11158-7 320 $aIncludes bibliographical references. 327 $a""Front matter ""; ""Acknowledgments""; ""Contents""; ""Summary""; ""Introduction""; ""1 Security Context for the Biological Threat Reduction Program""; ""2 Achievements of the Biological Threat Reduction Program""; ""3 U.S. Government-Wide Biological Threat Reduction Programs and Interagency Coordination""; ""4 Overcoming Obstacles Confronting the Biological Threat Reduction Program""; ""5 Future of the Biological Threat Reduction Program""; ""6 Recommendations""; ""Appendix A National Research Council Committee on Prevention of Proliferation of Biological Weapons"" 327 $a""Appendix B Extracts from Recent National Research Council Reports""""Appendix C Relevant Reports by the National Academies""; ""Appendix D Relevant Recent Reports by the U.S. Government Accountability Office""; ""Appendix E Other Reports of Interest""; ""Appendix F Research Projects Supported under the Cooperative Biological Research Program (1999-present)""; ""Appendix G Agenda""; ""Appendix H Foreign Colleagues Who Participated in Discussions of BTRP in Garmisch, Germany (April 2007)"" 606 $aBiological arms control 606 $aBiological weapons$xResearch$xSafety measures 606 $aBioterrorism$xPrevention 606 $aBiological warfare$xPrevention 615 0$aBiological arms control. 615 0$aBiological weapons$xResearch$xSafety measures. 615 0$aBioterrorism$xPrevention. 615 0$aBiological warfare$xPrevention. 676 $a327.1 712 02$aNational Research Council (U.S.).$bCommittee on Prevention of Proliferation of Biological Weapons. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910778373703321 996 $aThe Biological Threat Reduction Program of the Department of Defense$93856175 997 $aUNINA LEADER 04643nam 2200529 450 001 9910824862503321 005 20220923170517.0 010 $a0-231-51998-2 024 7 $a10.7312/chew14856 035 $a(CKB)3170000000065121 035 $a(DE-B1597)458745 035 $a(OCoLC)861793266 035 $a(OCoLC)979969460 035 $a(DE-B1597)9780231519984 035 $a(Au-PeEL)EBL3029386 035 $a(CaPaEBR)ebr10975969 035 $a(CaONFJC)MIL853666 035 $a(MiAaPQ)EBC3029386 035 $a(EXLCZ)993170000000065121 100 $a20141121h20092009 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aU.S. corporate governance /$fedited by Donald H. Chew and Stuart L. Gillan 210 1$aNew York ;$aChichester, England :$cColumbia University Press,$d2009. 210 4$dİ2009 215 $a1 online resource (380 pages) $cillustrations 225 0 $aColumbia Business School Publishing 300 $a"Columbia Business School Publishing"--Cover. 311 $a0-231-14857-7 320 $aIncludes bibliographical references and index. 327 $tFrontmatter --$tContents --$tIntroduction --$tPart I: Broad Perspectives on Corporate Governance --$t1. Value Maximization, Stakeholder Theory, and the Corporate Objective Function /$rJensen, Michael C. --$t2. The State of U.S. Corporate Governance: What's Right and What's Wrong? /$rHolmstrom, Bengt / Kaplan, Steven N. --$t3. U.S. Corporate Governance: Accomplishments and Failings: A Discussion with Michael Jensen and Robert Monks /$rJensen, Michael / Monks, Robert --$tPart II: Internal Governance: Boards and Executive Compensation --$t4. The Director's New Clothes (or, The Myth of Corporate Accountability) /$rMonks, Robert / Minow, Nell --$t5. Best Practices in Corporate Governance: What Two Decades of Research Reveals / /$rShivdasani, Anil / Zenner, Marc --$t6. Pay without Performance: Overview of the Issues /$rBebchuk, Lucian A. / Fried, Jesse M. --$t7. Is U.S. CEO Compensation Broken? /$rCore, John E. / Guay, Wayne R. / Thomas, Randall S. --$tPart III: External Governance: Ownership Structure --$t8. Just Say No to Wall Street: Putting a Stop to the Earnings Game /$rFuller, Joseph / Jensen, Michael C. --$t9. Identifying and Attracting the "Right" Investors: Evidence on the Behavior of Institutional Investors /$rBushee, Brian --$t10. U.S. Family- Run Companies- They May Be Better Than You Th ink /$rMcVey, Henry / Draho, Jason --$t11. The Evolution of Shareholder Activism in the United States /$rGillan, Stuart L. / Starks, Laura T. --$tPart IV: External Governance: The Market for Corporate Control --$t12. Corporate Control and the Politics of Finance /$rJensen, Michael C. --$t13. Where M&A Pays and Where It Strays: Survey of the Research /$rBruner, Robert --$t14. 14. Private Equity, Corporate Governance, and the Reinvention of the Market for Corporate Control /$rWruck, Karen H. --$tAbout the Contributors --$tIndex 330 $aCorporate governance constitutes the internal and external institutions, markets, policies, and processes designed to help companies maximize their efficiency and value. In this collection of classic and current articles from the Journal of Applied Corporate Finance, thought leaders such as Michael Jensen and Robert Monks discuss the corporate mission of value maximization and the accomplishments and limitations of the U.S. governance system in achieving that end. Essays address the elements driving corporate value: the board of directors, compensation for CEOs and other employees, incentives and organizational structure, external ownership and control, role of markets, and financial reporting. They evaluate best practice methods, challenges in designing equity plans, transferable stock options, the controversy over executive compensation, the values of decentralization, identifying and attracting the "right" investors, the evolution of shareholder activism, creating value through mergers and acquisitions, and the benefits of just saying no to Wall Street's "earnings game." Grounded in solid research and practice, U.S. Corporate Governance is a crucial companion for navigating the world of modern finance. 606 $aCorporate governance$zUnited States 615 0$aCorporate governance 676 $a338.60973 702 $aChew$b Donald H. 702 $aGillan$b Stuart L. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910824862503321 996 $aU.S. corporate governance$94072064 997 $aUNINA